Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study)

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 22, Issue 8, 2015, Pages 634-645

  Hatano, Etsuro ^a   Okuno, Masayuki ^a   Nakamura, Kojiro ^a   Ishii, Takamichi ^a   Seo, Satoru ^a   Taura, Kojiro ^a   Yasuchika, Kentaro ^a   Yazawa, Takefumi ^b   Zaima, Masazumi ^b   Kanazawa, Akiyoshi ^c   Terajima, Hiroaki ^d   Kaihara, Satoshi ^e   Adachi, Yukihito ^f   Inoue, Naoya ^g   Furumoto, Katsuyoshi ^h   Manaka, Dai ⁱ   Tokka, Atsuo ^j   Furuyama, Hiroaki ^k   Doi, Koji ^l   Hirose, Tetsuro ^m   Horimatsu, Takahiro ⁿ   Hasegawa, Suguru ^a   Matsumoto, Shigemi ⁿ   Sakai, Yoshiharu ^a   Uemoto, Shinji ^a   more..

^a KYOTO UNIVERSITY   (Japan)

^b Shiga Medical Center for Adult Diseases   (Japan)

^c OSAKA RED CROSS HOSPITAL   (Japan)

^d Kitano Hospital   (Japan)

^e KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^f Saiseikai Noe Hospital   (Japan)

^g KANSAI ELECTRIC POWER CO   (Japan)

^h Kishiwada City Hospital   (Japan)

ⁱ KYOTO KATSURA HOSPITAL   (Japan)

^j SHIMANE PREFECTURAL CENTRAL HOSPITAL   (Japan)

^k TENRI HOSPITAL   (Japan)

^l FUKUI PREFECTURAL HOSPITAL   (Japan)

^m TAKAMATSU RED CROSS HOSPITAL   (Japan)

ⁿ KYOTO UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Colorectal liver metastasis; Conversion; Hepatic resection; Resectability

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; CURATIVE RESECTION RATE; DIZZINESS; DRUG EFFICACY; FEMALE; HUMAN; LIVER RESECTION; LONG TERM SURVIVAL; MALE; MORBIDITY; MOUTH ULCER; MULTICENTER STUDY; NAUSEA; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PERCUTANEOUS DRAINAGE; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSORY NEUROPATHY; SKIN TOXICITY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; WILD TYPE; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; ONCOGENE RAS; PATHOLOGY; SECONDARY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENES, RAS; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES;

EID: 84937525678     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.254     Document Type: Article

References (38)

1. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier A-M. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006; 244: 254-9.
2. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006; 93: 465-74.
3. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: A population-based study. Cancer. 2007; 109: 718-26.
4. Jaeck D, Bachellier P, Guiguet M, Boudjema K, Vaillant JC, Balladur P, et al. Long-term survival following resection of colorectal hepatic metastases. Br J Surg. 1997; 84: 977-80.
5. Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol. 2007; 14: 1151-60.
6. Nathan H, de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, et al. Conditional survival after surgical resection of colorectal liver metastasis: An international multi-institutional analysis of 949 patients. J Am Coll Surg. 2010; 210: 755-64.
7. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg. 1990; 77: 1241-6.
8. Pearson RK. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. Yearb Gastroenterol. 2010; 2010: 91-3.
9. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, De Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 27: 663-71.
10. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004; 240: 644-57; discussion 657-8.
11. Morris EJA, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg. 2010; 97: 1110-18.
12. Power DG, Kemeny NE. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Crit Rev Oncol Hematol. 2011; 79: 251-64.
13. Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol. 2005; 16: 1311-19.
14. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26: 2013-19.
15. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer. 2009; 101: 1033-8.
16. Clavien P-A, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med. 2007; 356: 1545-59.
17. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240: 205-13.
18. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004; 22: 229-37.
19. De Gramont A, Figer M, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 2938-47.
20. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005; 23: 4866-75.
21. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-A GERCOR study. J Clin Oncol. 2006; 24: 394-400.
22. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Dibartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol. 2009; 20: 1842-7.
23. Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007; 25: 5225-32.
24. Folprecht G, Gruenberger T, Bechstein WO, Raab H-R, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010; 11: 38-47.
25. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005; 23: 9243-9.
26. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009; 249: 420-5.
27. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011; 22: 2042-8.
28. Ji JH, Park SH, Lee J, Kim TW, Hong YS, Kim KP, et al. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. Cancer Chemother Pharmacol. 2013; 72: 223-30.
29. Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, et al. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study. Int J Clin Oncol. 2013; 18: 335-42.
30. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013; 31: 1931-8.
31. Beppu, T, Emi Y, Tokunaga S, Oki E, Shirabe K, Ueno S, et al. Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study). Anticancer Res. 2014; 34: 6655-62.
32. Folprecht G, Gruenberger T, Bechstein W, Raab H-R, Weitz J, Lordick F, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014; 25: 1018-25.
33. Uetake H, Yasuno M, Ishiguro M, Kameoka S, Shimada Y, Takahashi K, et al. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808). Ann Surg Oncol. 2015; 22: 908-15.
34. Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2014. doi: 10.1093/annonc/mdu580.
35. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996; 224: 509-20; discussion 520-2.
36. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999; 10: 663-9.
37. Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003; 46: S22-31.
38. Yamaguchi T, Mori T, Takahashi K, Matsumoto H, Miyamoto H, Kato T. A new classification system for liver metastases from colorectal cancer in Japanese multicenter analysis. Hepatogastroenterology. 2008; 55: 173-8.